UBS’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$1.41M Sell
8,800
-1,900
-18% -$292K ﹤0.01% 3247
2014
Q2
$1.57M Buy
10,700
+1,800
+20% +$250K ﹤0.01% 3115
2014
Q1
$1.23M Sell
8,900
-16,600
-65% -$2.5M ﹤0.01% 3278
2013
Q4
$3.23M Buy
25,500
+8,000
+46% +$828K ﹤0.01% 2311
2013
Q3
$1.61M Buy
17,500
+14,600
+503% +$1.18M ﹤0.01% 2826
2013
Q2
$199K Buy
+2,900
New +$177K ﹤0.01% 5102

Other funds holding JAZZ

UBS's JAZZ Position: Q3 2014 in Review

UBS reduced its Jazz Pharmaceuticals (JAZZ) stake by 56% in Q3 2014, selling an estimated $28.7M and leaving 145,410 shares worth $23.3M. The position accounts for 0.02% of the portfolio, ranked #867.

UBS first reported a position in JAZZ in Q2 2013 and has held it in 6 quarters since. The position peaked at $48.9M in Q2 2014. 325 funds tracked by Wall St. Rank hold JAZZ as of Q3 2014.

  • UBS held 145,410 shares of Jazz Pharmaceuticals worth $23.3M as of Q3 2014.
  • UBS sold 186,966 Jazz Pharmaceuticals shares in Q3 2014, an estimated $28.7M.
  • Jazz Pharmaceuticals made up 0.02% of UBS's portfolio in Q3 2014, its #867 holding.
  • UBS first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • UBS's Jazz Pharmaceuticals position peaked at $48.9M in Q2 2014.
  • 325 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.